Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice GuidelineJulie R. Brahmer, John A. Thompson, Christina Lacchetti et al.|Journal of Clinical Oncology|2018Cited by 3.7k
Treatment of Metastatic Melanoma with Autologous CD4+ T Cells against NY-ESO-1Naomi Hunder, Cassian Yee, John A. Thompson et al.|New England Journal of Medicine|2008Cited by 903
Preexisting Autoimmune Disease: Implications for Immune Checkpoint Inhibitor Therapy in Solid TumorsLaura C. Kennedy, Petros Grivas, Shailender Bhatia et al.|Journal of the National Comprehensive Cancer Network|2019Cited by 116
First-in-human phase I/Ib study of NIZ985, a recombinant heterodimer of IL-15 and IL-15Rα, as a single agent and in combination with spartalizumab in patients with advanced and metastatic solid tumorsRom S. Leidner, John A. Thompson|Journal for ImmunoTherapy of Cancer|2023Cited by 23